Contains Nonbinding Recommendations

Draft Guidance on Minocycline Hydrochloride

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Minocycline Hydrochloride

Form/Route: Capsule (Extended release)/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 135 mg (base)
   Subjects: Healthy males and non-pregnant females, general population.
   Additional Comment: The capsules should be swallowed whole without chewing, crushing or splitting.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 135 mg (base)
   Subjects: Healthy males and non-pregnant females, general population.
   Additional Comment: The capsules should be swallowed whole without chewing, crushing or splitting.

Analytes to measure: Minocycline in plasma

Bioequivalence based on (90% CI): Minocycline

Approval of other strengths: 45 mg (base), 67.5 mg (base), 90 mg (base), 112.5 mg (base), based on (i) acceptable bioequivalence studies on the 135 mg (base) strength, (ii) proportional similarity in the formulations of the 45 mg (base), 67.5 mg (base), 90 mg (base), 112.5 mg (base), and 135 mg (base) strengths and (iii) acceptable in vitro dissolution testing on all strengths.

Dissolution test method: Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative drug dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application. In addition to the method above, for modified release products, dissolution profiles on 12 dosage units each of test and reference products generated using USP Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in at least three dissolution media (pH 1.2, 4.5 and 6.8 buffer) should be submitted in the application. Agitation speeds may have to be increased if appropriate. It is

Recommended Apr 2013
acceptable to add a small amount of surfactant, if necessary. Please include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation. Specifications will be determined upon review of the data submitted in the application.